The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024

NOW IN ELEVEN EDITIONS—The Worldwide Market for Point-of-Care (POC) Diagnostic Tests forecasts the POC market through 2028.

Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in vitro diagnostics (IVD) industry. However, the point-of-care (POC) segment is seen as a key growth area. Point-of-care refers to tests that can provide meaningful results during a provider visit or in the patient's home.

Over the past two decades, Kalorama Information has observed that POC tests present significant opportunities for expansion. This rich history analyzing the market is at the forefront of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024, the eleventh edition in Kalorama’s POC report series.

The role of diagnostics in promoting wellness, improving patient-provider encounters, aiding in drug selection and stewardship, facilitating home or nursing home care, and ensuring effective pandemic management relies heavily on the success of point-of-care solutions. The global POC testing market has experienced significant growth in the last two decades due to the increasing demand for accurate and rapid testing, both within and outside hospital settings. Technological advancements in smartphones, biosensors, lab-on-a-chip, and wearable devices have influenced the POC landscape, aiming to provide expedited diagnosis at the point-of-care.

As a result, point-of-care diagnostics can command higher pricing and experience larger revenue growth compared to lab-based tests. The tests covered in The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 tend to grow at higher rates than the overall IVD market.

Enhanced Segmentation - Many Reports in One

The report delves into various areas of POC diagnostics, including:

• Glucose
• Coagulation
• CRP
• Other Cardiac Markers
• Coagulation
• Colon Cancer
• Pregnancy / Fertility
• Drugs of Abuse
• hbA1c
• Cholesterol
• HIV
• COVID-19
• Other Infectious Disease
• Critical Care Tests

Each area is thoroughly analyzed, providing market sizing and forecasts.

Venue Market Analysis

POC tests are conducted in various settings, including hospital departments (emergency, operating rooms, intensive care units), physicians' offices, hospital clinics, retail clinics, pharmacies, homes (self-testing or by caregivers), and nursing homes.

POC testing may be performed by laboratory personnel, but often it is performed by non-laboratory personnel such as physicians, nurses, assistants in medical offices, emergency medical technicians (EMTs), medics, pharmacists, and the patients themselves (self-testing). Some POC tests are manual tests, often performed with technologies based on dipsticks or strips, lateral flow cassettes, or other manual tests. There are also many small, portable instruments that have been developed for use in POC settings. With the advances in miniaturization and microfluidics that have occurred in recent years, a growing number of small, handheld devices are reaching the POC market for a range of different testing applications.

Regional Coverage

POC is an international market and Kalorama reflects this with regional coverage.  Analysis is anchored by:

• Europe
• Japan
• United States
• Rest of World

Other countries and regions discussed in the report include:

• Australia
• Canada
• China
• France
• Germany
• India
• Italy
• South Korea
• Spain
• Sweden
• Switzerland
• Latin America
• Middle East

Corporate Profiles

The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 also highlights the contribution of POC test devices to the overall diagnostics market growth. More diagnostic manufacturers are seeking CLIA waiver status or CE Mark for their POC devices, indicating the growing importance of POC testing in diagnosis and patient care monitoring. Rapid tests are also becoming more prevalent in the POC arena, allowing physicians to treat patients more effectively and efficiently.

This report breaks out point-of-care testing by segment.

Among the top and/or innovative competitors discussed within Corporate Profiles are:

• 1 Step Detect Associates
• Abbott Labs
• Abingdon Health
• Access Bio
• AccuBioTech
• ACON Laboratories
• Aerscher Diagnostics
• Alfa Scientific Designs
• American Bio Medica
• ARKRAY
• Artron Laboratories
• Ascensia Diabetes Care
• Atlas Link Biotech
• Autobio Diagnostics
• Beckman Coulter
• Becton Dickinson
• Beijing Wantai Biological Pharmaceuticals
• Bhat Bio-Tech India Private Ltd.
• Binx health
• bioLytical Laboratories
• BioMedomics
• Biomeme
• Biomerica
• bioMérieux SA
• Biophor Diagnostics
• Bio-Rad Laboratories
• Biosensia
• Biotron Diagnostics
• Boditech Med
• Boson Biotech
• BTNX
• Cepheid
• Chembio Diagnostic Systems
• Church & Dwight
• Clarity Diagnostics
• Confirm Biosciences
• CTK Biotech
• Cue Health
• Danaher Corporation
• Dexcom
• DIALAB
• DiaSys Diagnostic Systems
• Diazyme Laboratories
• DNA Electronics Ltd.
• Dr Fooke-Achterrath
• DxGen
• Eiken Chemical
• EKF Diagnostics
• ELITechGroup, Inc
• Enterix
• Eurobio Scientific
• Eurolyser Diagnostica
• Everlywell
• Exact Sciences
• EY Laboratories
• Fio Corp
• First Check Diagnostics
• GenBio
• Genedrive
• GenePOC
• GeTein BioMedical
• Helena Labs
• Hemosure
• HORIBA
• Immune IQ
• Immunosciences Lab
• Immunostics
• JAL Innovation
• Jant Pharmacal
• J. Mitra & Co
• Kypha
• LamdaGen Corp
• LifeScan
• LifeSign
• LightDeck Diagnostics
• LumiraDx
• Macherey-Nagel
• Medix Biochemica
• MedMira
• Medtronic
• Menarini Diagnostics
• Meridian BioScience
• MiCo BioMed
• Nano-Ditech Corporation
• Nexus Dx
• NG Biotech
• Noble Medical
• Nova Biomedical
• Oasis Diagnostics
• Operon
• OPKO Health
• OraSure Technologies
• PixCell Medical Technologies
• Polymedco
• Polymer Technologies
• Preventis
• Princeton Biomeditech
• QuantuMDx Group
• QuidelOrtho
• Radiometer Medical
• Randox Labs
• Response Biomedical
• Reszon Diagnostics
• Rheonix
• Roche Diagnostics
• Savyon Diagnostics
• Sekisui Diagnostics
• Siemens Healthcare
• Sysmex
• TECHLAB
• Teco Diagnostics
• Trinity Biotech
• Trividia Health
• Tulip Diagnostics
• VedaLab
• Werfen

Scope and Methodology

The Worldwide Market for Point-of-Care (POC) Diagnostic Tests is now in its eleventh edition, reflecting more than two decades of Kalorama’s analysis of the POC market.

The  geographic scope of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 is global, with information for specific geographical regions, world demographics, and other general issues affecting the market. The report’s market summary includes total market values, market analysis by product, test usage, technology, region, end-use and a competitive analysis of leading providers. Additionally, key company profiles are included.

All market data pertains to the world market at the manufacturers’ level. The market includes manufacturer tests excluding services.  The base year for data was 2023. Forecast data is provided for 2023 through 2028. Compound annual growth rates (CAGRs) are provided for the 2023-2028 period for each segment covered.  Competitive analysis is provided for the year 2023 along with regional breakdowns.  The forecasted market analysis for 2023-2028 was largely based on demographic trends, new developments, innovative technology and global expansion.